BioArctic Q3: Encouraging clinical data

Research Note

2020-10-14

10:04

Redeye maintains BioArctic's fair value at SEK 150 per share, an upside of more than 70% from current stock price levels. Q3 has offered a string of positive news about the efficacy and safety of BAN2401, and further progress in the pipeline. In the context of these developments and the solid cash position, the company is currently greatly undervalued, in our view. 

GA

Gergana Almquist

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.